Taysha Gene Therapies (NASDAQ:TSHA) Lowered to "Sell" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Taysha Gene Therapies from “hold” to “sell,” adding to a mixed analyst backdrop that still leans positive overall.
• The stock has a consensus Buy rating from analysts, with 2 Strong Buy, 10 Buy, and 1 Sell ratings, and a consensus price target of $11.64.
• Recent results showed the company missed earnings estimates, reporting EPS of ($0.12) versus expectations of ($0.10), while shares opened at $6.81 and have traded near their 52-week high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

Other equities analysts have also recently issued reports about the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Taysha Gene Therapies in a research note on Friday, March 27th. Truist Financial upgraded Taysha Gene Therapies to a "strong-buy" rating in a research note on Wednesday, March 25th. Chardan Capital restated a "buy" rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Needham & Company LLC raised their price objective on Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Thursday, March 19th. Finally, Canaccord Genuity Group raised their price objective on Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a "buy" rating in a research note on Monday, April 6th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Taysha Gene Therapies presently has a consensus rating of "Buy" and a consensus price target of $11.64.

Taysha Gene Therapies Stock Performance

Taysha Gene Therapies stock opened at $6.81 on Friday. The stock has a market cap of $1.96 billion, a P/E ratio of -17.92 and a beta of 1.25. The company has a current ratio of 12.23, a quick ratio of 12.23 and a debt-to-equity ratio of 0.20. The stock has a 50 day moving average of $5.07 and a 200-day moving average of $4.93. Taysha Gene Therapies has a 52 week low of $2.06 and a 52 week high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). On average, analysts expect that Taysha Gene Therapies will post -0.41 EPS for the current fiscal year.

Insider Transactions at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of the firm's stock in a transaction on Friday, April 10th. The stock was sold at an average price of $4.46, for a total transaction of $892,000.00. Following the transaction, the insider directly owned 1,136,410 shares in the company, valued at $5,068,388.60. This trade represents a 14.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.78% of the stock is owned by company insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

Several large investors have recently added to or reduced their stakes in the company. Marex Group plc acquired a new stake in Taysha Gene Therapies in the second quarter worth $29,000. E Fund Management Co. Ltd. acquired a new stake in Taysha Gene Therapies in the second quarter worth $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in Taysha Gene Therapies in the third quarter worth $40,000. Tower Research Capital LLC TRC increased its position in Taysha Gene Therapies by 156.5% in the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company's stock worth $41,000 after buying an additional 10,742 shares during the period. Finally, Caitong International Asset Management Co. Ltd increased its position in Taysha Gene Therapies by 143.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company's stock worth $43,000 after buying an additional 4,607 shares during the period. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.